10Nov/25
Targeting Drug-Resistant Breast Cancer with a Novel ADC
Hormone receptor-positive, HER2-negative breast cancer (HR+/HER2- BC) represents a significant fraction of all breast cancer diagnoses. While conventional treatment with endocrine therapy (ET) and CDK4/6 inhibitors has improved clinical outcomes, the developmentRead More…